Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Prospective Cohort Study in Patients With NAFLD

Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with diagnosed by tissue sample (biopsy-confirmed) fatty liver disease Who Should NOT Join This Trial: - History of significant alcohol consumption - Viral hepatitis - Autoimmune hepatitis - Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency) - Hepatotoxic medication (e.g. amiodarone). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * Patients with histologically confirmed fatty liver disease Exclusion criteria: * History of significant alcohol consumption * Viral hepatitis * Autoimmune hepatitis * Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency) * Hepatotoxic medication (e.g. amiodarone).

Locations (1)

University Hospital Zurich, Endocrinology and Diabetology
Zurich, Canton of Zurich, Switzerland